Last reviewed · How we verify
oral suzetrigine
Suzetrigine is a selective sodium channel blocker that reduces neuronal excitability and pain signal transmission.
Suzetrigine is a selective sodium channel blocker that reduces neuronal excitability and pain signal transmission. Used for Chronic pain conditions (specific indication pending confirmation of marketed status).
At a glance
| Generic name | oral suzetrigine |
|---|---|
| Sponsor | University of Louisville |
| Drug class | Selective sodium channel blocker |
| Target | Voltage-gated sodium channels (Nav) |
| Modality | Small molecule |
| Therapeutic area | Pain management / Neurology |
| Phase | FDA-approved |
Mechanism of action
Suzetrigine selectively inhibits voltage-gated sodium channels, particularly in pain-sensing neurons, thereby reducing the generation and propagation of action potentials involved in pain signaling. By blocking sodium influx, it dampens neuronal firing without significantly affecting normal motor or cognitive function, making it suitable for chronic pain management.
Approved indications
- Chronic pain conditions (specific indication pending confirmation of marketed status)
Common side effects
- Dizziness
- Headache
- Nausea
- Fatigue
Key clinical trials
- Suzetrigine for Non-Mastectomy Breast Surgery (PHASE4)
- Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy (PHASE3)
- Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants (PHASE1)
- Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy (PHASE3)
- Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN) (PHASE3)
- Evaluating Suzetrigine for Pain Control Following TKA (PHASE3)
- A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries (PHASE4)
- A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- oral suzetrigine CI brief — competitive landscape report
- oral suzetrigine updates RSS · CI watch RSS
- University of Louisville portfolio CI